Argent Biopharma Limited has released a press release.
Australian Legislation Changes Fast Track MXC
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Argent Biopharma
- Cannabinoid Extraction Facility On Target Q2 Production
- Medical Cannabis Clinical Study Commencing
- Panax Acquisition Completed
- Commencement of Dermatological Clinical Trials
- European CPNP Approval Granted for Derma Products
Later from Argent Biopharma
- Placement of $10m Closed Significantly Oversubscribed
- European API Extraction Facility Completed
- Successful MXC First Cannabinoid Production
- New EU Sales Agreements Signed For MGC Derma
- Strategic Agreement Signed with RMIT
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma